Cepheid CFO Sells $111,907 in Stock (CPHD)
Cepheid (NASDAQ:CPHD) CFO Andrew Miller sold 2,437 shares of Cepheid stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $45.92, for a total value of $111,907.04. Following the sale, the chief financial officer now directly owns 2,683 shares of the company’s stock, valued at approximately $123,203. The transaction was disclosed in a filing with the SEC, which is available at this link.
Cepheid (NASDAQ:CPHD) traded down 0.24% during mid-day trading on Friday, hitting $45.75. The stock had a trading volume of 420,683 shares. Cepheid has a 1-year low of $30.95 and a 1-year high of $47.21. The stock has a 50-day moving average of $45.14 and a 200-day moving average of $38.93. The company’s market cap is $3.103 billion.
Cepheid (NASDAQ:CPHD) last announced its earnings results on Thursday, October 17th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.09. The company had revenue of $100.10 million for the quarter, compared to the consensus estimate of $93.70 million. During the same quarter in the previous year, the company posted ($0.32) earnings per share. The company’s revenue for the quarter was up 25.6% on a year-over-year basis.
Several analysts have recently commented on the stock. Analysts at Needham & Company initiated coverage on shares of Cepheid in a research note to investors on Thursday, December 19th. They set a “hold” rating on the stock. Separately, analysts at JMP Securities initiated coverage on shares of Cepheid in a research note to investors on Wednesday, December 18th. They set a “market perform” rating on the stock. Finally, analysts at UBS AG raised their price target on shares of Cepheid from $44.00 to $48.00 in a research note to investors on Friday, December 13th. They now have a “buy” rating on the stock. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $43.26.
Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.